# Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

> **NCT05159193** · PHASE3 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 372 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** pegylated liposomal doxorubicin (PLD)
- **DRUG:** cyclophosphamide (C)
- **DRUG:** trastuzumab (H)
- **DRUG:** pertuzumab (P)
- **DRUG:** docetaxel (T)
- **DRUG:** docetaxel (T)
- **DRUG:** carboplatin (Cb)
- **DRUG:** trastuzumab (H)
- **DRUG:** pertuzumab (P)

## Key facts

- **NCT ID:** NCT05159193
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-20
- **Primary completion:** 2024-10-30
- **Final completion:** 2028-01-31
- **Target enrollment:** 372 (ESTIMATED)
- **Last updated:** 2024-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05159193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05159193, "Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05159193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*